Siliphos in Advanced Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Collaborator:
Lotte & John Hecht Memorial Foundation
Information provided by (Responsible Party):
Abby Siegel, Columbia University
ClinicalTrials.gov Identifier:
NCT01129570
First received: April 12, 2010
Last updated: November 21, 2013
Last verified: November 2013
  Purpose

Milk thistle is an herbal drug that may have some liver protection properties and may reduce inflammation in the liver. It may also have anticancer effects. However milk thistle is not approved by the Food and Drug Administration for any medical purpose in the United States.

It has not been used in patients with liver cancer previously, to our knowledge, but there have been many studies of its use in patients with hepatitis and cirrhosis. Some of these studies have shown that milk thistle may help reduce elevated liver function tests.

Siliphos is a derivative of milk thistle that can be absorbed better than some other types of milk thistle. The investigators would like to perform a study to identify doses of siliphos that are safe to take in advanced liver cancer and to identify positive or negative side effects this compound may have. The investigators will be using this information in future studies to see if siliphos can be used as a therapy in patients with advanced liver cancer to reduce elevated liver function tests.


Condition Intervention Phase
Advanced Hepatocellular Carcinoma
Drug: Silybin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Columbia University:

Primary Outcome Measures:
  • The maximum tolerated dose of siliphos in patients with advanced hepatocellular carcinoma [ Time Frame: Weeks 1, 3, 6, 9, and 12 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mean intra-patient percent change in AST, ALT and total serum bilirubin levels [ Time Frame: From baseline to 3 months ] [ Designated as safety issue: No ]
    Fasting morning blood samples collected at baseline, weeks 1, 3, 6, 9, and 12

  • Quality of life as measured by the FACT-hepatobiliary questionnaire [ Time Frame: From baseline to 3 months ] [ Designated as safety issue: No ]
    Questionnaire administered at baseline, weeks 1, 6, and 12

  • Plasma concentrations of silybinin, silybinin B, silibinin glucoronide, and silibinin sulfate [ Time Frame: From baseline to 3 months ] [ Designated as safety issue: No ]
    Fasting morning blood samples collected at baseline, weeks 1, 3, 6, 9, and 12

  • Mean intra-patient percent change in serum concentrations of CRP, IGF-1, and IGFBP-3 [ Time Frame: From baseline to 3 months ] [ Designated as safety issue: No ]
    Fasting morning blood samples collected at baseline, weeks 1, 3, 6, and 12

  • Tumor response as measured by RECIST criteria and AFP concentrations [ Time Frame: From baseline to 3 months ] [ Designated as safety issue: No ]

    Fasting blood samples collected at baseline, weeks 1, 3, 6, 9, and 12 for AFP concentrations.

    MRI of abdomen/pelvis & CT of chest at baseline and week 12



Enrollment: 3
Study Start Date: February 2010
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Siliphos - dose escalation Drug: Silybin
4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
Other Names:
  • Siliphos
  • Milk thistle
  • Advanced hepatocellular carcinoma

Detailed Description:

Milk thistle (MT) has been historically used to treat patients with liver diseases, and has been shown to have antioxidant, anti inflammatory, and hepatoprotective properties. It may also have direct anticancer effects through inhibition of growth factors and promotion of cell cycle arrest. MT has been shown to improve LFTs in several studies of patients with cirrhosis. To our knowledge, there have been no published trials evaluating the clinical efficacy of MT in advanced HCC. We therefore propose a phase I study to identify the maximum tolerated dose (MTD) of silybinphosphatidylcholine (a commercially available preparation with increased bioavailability), in patients with advanced HCC. We will use a traditional dose escalation, open label design with a study intervention period of 3 months, followed by one year of observation, with a maximum total of 30 subjects, evaluating a dose range between 1 to 12 gm Siliphos. The data obtained from this study will be utilized in the future to evaluate MT efficacy in reducing liver function tests in advanced HCC, which will have significant implications in its use as a potential adjunctive agent in patients with currently limited treatment options.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • ECOG performance score of 0-3
  • Expected survival of >12 weeks
  • Subjects with advanced HCC or locally advanced, unresectable HCC
  • Elevated LFTs (including at least one of the following: TBili >1.5 times the upper limit of normal; serum AST >2.5 times the upper limit of normal
  • HCC diagnosed/defined based on either biopsy, or by suggestive radiologic imaging according to the AASLD guidelines (arterial enhancement with venous washout) or an AFP >200 ng/ml
  • Subjects must have measurable disease that can be accurately measured in at least one dimension (with at least >20mm diameter in the longest dimension by conventional imaging or >10 mm by helical CT)
  • Elevated liver enzymes that are either due to underlying liver disease and/or tumor which is not amenable to stenting after discussion with interventional GI and/or IR
  • Subjects must demonstrate an ability to understand the consent process and willingness to sign a written informed consent form
  • Subjects must agree to use birth control pills or other active contraception during active study treatment

Exclusion Criteria:

  • Pregnant women or women currently breastfeeding will be excluded from this study because the effects of silybin on pregnant women and/or nursing infants are not known
  • Subjects must have < grade 4 hepatic toxicity
  • Known brain metastases because of poor prognosis and as patients with brain metastases often develop neurological dysfunction that may confound evaluation of neurologic and other adverse side effects
  • History of allergic reactions to the study medication
  • Uncontrolled concurrent illness including, but not limited to: ongoing active infection (including SBP), symptomatic congestive heart failure, unstable angina, active cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01129570

Locations
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Abby Siegel
Lotte & John Hecht Memorial Foundation
Investigators
Principal Investigator: Abby Siegel, MD, MS Columbia University
  More Information

No publications provided

Responsible Party: Abby Siegel, Assistant Professor of Clinical Medicine, Oncology, Columbia University
ClinicalTrials.gov Identifier: NCT01129570     History of Changes
Other Study ID Numbers: AAAE7604
Study First Received: April 12, 2010
Last Updated: November 21, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Carcinoma
Adenocarcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on October 01, 2014